ARDENT HEALTH INC (ARDT) Forecast, Price Target & Analyst Ratings
NYSE:ARDT • US03980N1072
8.9 USD
-0.54 (-5.72%)
At close: Mar 6, 2026
8.61 USD
-0.29 (-3.26%)
After Hours: 3/6/2026, 8:04:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARDENT HEALTH INC (ARDT).
Forecast Snapshot
Consensus Price Target
$13.98
+ 57.12% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate$0.24
Revenue Estimate1.623B
ChartMill Buy Consensus
77.89%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$13.98
Upside
+ 57.12%
From current price of $8.90 to mean target of $13.98, Based on 19 analyst forecasts
Low
$8.89
Median
$14.28
High
$17.85
Price Target Revisions
1 Month
-0.18%
3 Months
-15.64%
Price Target Summary
19 analysts have analysed ARDT and the average price target is 13.98 USD. This implies a price increase of 57.12% is expected in the next year compared to the current price of 8.9.
The average price target has been revised downward by 15.64% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
77.89%
ARDT was analyzed by 19 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about ARDT.
In the previous month the buy percentage consensus was at a similar level.
ARDT was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-06 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-01-20 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-12-18 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-18 | UBS | Maintains | Buy -> Buy |
| 2025-11-24 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-18 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-18 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-17 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2025-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-14 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-11-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-11-13 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-10-14 | Goldman Sachs | Initiate | Neutral |
| 2025-09-10 | UBS | Initiate | Buy |
| 2025-08-11 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-08-07 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-07-16 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2025-05-20 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-05-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-04-09 | Guggenheim | Initiate | Buy |
| 2025-04-01 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-26 | Stephens & Co. | Reiterate | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate$0.24
Revenue Estimate1.623B
Revenue Q2Q8.40%
EPS Q2Q-18.71%
Number of Analysts12
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.42%
EPS (1 Month)
12.34%
EPS (3 Months)
-18.40%
Next Earnings Summary
ARDT is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is 0.24 USD and the consensus revenue estimate is 1.62B USD.
The next earnings revenue estimate has been revised upward by 0.42% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.13B 5.32% | 5.409B 5.45% | 5.966B 10.29% | 6.477B 8.56% | 6.784B 4.74% | 7.171B 5.70% | 7.862B 9.64% | |
| EBITDA YoY % growth | 338.426M -23.15% | 356.685M 5.40% | 552.05M 54.77% | 551.77M -0.05% | 537.74M -2.54% | 579.4M 7.75% | N/A | |
| EBIT YoY % growth | 200.253M -33.95% | 215.843M 7.79% | 405.762M 87.99% | 331.91M -18.20% | 397.16M 19.66% | 429.8M 8.22% | N/A | |
| Operating Margin | 3.90% | 3.99% | 6.80% | 5.12% | 5.85% | 5.99% | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | 0.99 34.18% | 1.37 -16.94% | 1.50 9.13% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.24 -18.71% | 0.42 -20.01% | 0.30 -42.02% | 0.48 48.45% | 0.31 31.25% | 0.46 11.17% | 0.31 2.63% | 0.51 7.36% |
| Revenue Q2Q % growth | 1.623B 8.40% | 1.712B 4.06% | 1.682B 6.68% | 1.779B 10.84% | 1.721B 6.04% | 1.818B 6.19% | 1.764B 4.88% | 1.878B 5.56% |
| EBITDA Q2Q % growth | 112.79M 9.20% | 147.19M -30.83% | 126.05M -3.87% | 163.33M 22.73% | 127.78M 13.29% | 154.49M 4.96% | 126.77M 0.57% | 172.75M 5.77% |
| EBIT Q2Q % growth | 78.164M 16.50% | 115.81M -15.64% | 94.731M 475.59% | 134.36M 36.12% | 92.958M 18.93% | 116.95M 0.98% | 84.737M -10.55% | 125.76M -6.40% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
6.67%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
17.14%
EBIT Next 5 Year
N/A
ARDENT HEALTH INC / ARDT Forecast FAQ
What do analysts expect the price target to be for ARDENT HEALTH INC (ARDT)?
19 analysts have analysed ARDT and the average price target is 13.98 USD. This implies a price increase of 57.12% is expected in the next year compared to the current price of 8.9.
Can you provide the upcoming earnings date for ARDENT HEALTH INC?
ARDENT HEALTH INC (ARDT) will report earnings on 2026-05-04.
Can you provide the consensus estimates for ARDENT HEALTH INC next earnings?
The consensus EPS estimate for the next earnings of ARDENT HEALTH INC (ARDT) is 0.24 USD and the consensus revenue estimate is 1.62B USD.
Can you provide the expected long term growth rate for ARDENT HEALTH INC stock?
The expected long term growth rate for ARDENT HEALTH INC (ARDT) is 6.67%.